Philadelphia, USA July 31, 2019 – MarketsandMarkets recently interviewed Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City.
Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention?
A. advances: more indication using ICI and combinations with chemo, and other IO. even brain metastases seem to respond to smart combinations. challenges: primary and secondary resistance and still less than 50% of patients even in effective areas are responding
Q. What are the new opportunities emerging in your field of work?
1. new indications (e.g. BrCa ) and lines of therapy e.g. earlier stages.
2. established chemotherapy combinations plus ICI and other IO
Q. What are the key take away points from your presentation topic which will help in building the knowledge base of attendees?
A. Chemotherapy should be one of the MOA to increase efficacy and make otherwise less responsive tumours sensitive to ICI. new indications should be explored
Q. Hope you had a chance to go through the agenda, what are your views on it and how helpful it is to the targeted audience?
A. all is actually well designed
Stefan Glueck will present his insights on “Update on ICI data in early and metastatic breast cancer”
The latest conference agenda and complete speaker line-up is available to download on the conference page, where you can also register – https://bit.ly/2LNkgpQ
For more inquiries contact Amit Shelke, Marketing Manager on email@example.com